416 related articles for article (PubMed ID: 21960212)
1. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
2. 25 years of small molecular weight kinase inhibitors: potentials and limitations.
Fabbro D
Mol Pharmacol; 2015 May; 87(5):766-75. PubMed ID: 25549667
[TBL] [Abstract][Full Text] [Related]
3. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
[TBL] [Abstract][Full Text] [Related]
6. Kinases as targets in the treatment of solid tumors.
Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
[TBL] [Abstract][Full Text] [Related]
7. Affinity purification of proteins binding to kinase inhibitors immobilized on self-assembling monolayers.
Bantscheff M; Hobson S; Kuster B
Methods Mol Biol; 2012; 795():149-60. PubMed ID: 21960221
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
9. Advancing the kinase field: new targets and second generation inhibitors.
Laufer S; Bajorath J
J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
[No Abstract] [Full Text] [Related]
10. Kinase domain mutations in cancer: implications for small molecule drug design strategies.
Bikker JA; Brooijmans N; Wissner A; Mansour TS
J Med Chem; 2009 Mar; 52(6):1493-509. PubMed ID: 19239229
[No Abstract] [Full Text] [Related]
11. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase inhibitors as a therapeutic modality.
Levitzki A
Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
[TBL] [Abstract][Full Text] [Related]
13. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
14. Protein kinases: From targets to anti-cancer drugs.
Cruzalegui F
Ann Pharm Fr; 2010 Jul; 68(4):254-9. PubMed ID: 20637357
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
16. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.
Fry DW
Anticancer Drug Des; 2000 Feb; 15(1):3-16. PubMed ID: 10888032
[TBL] [Abstract][Full Text] [Related]
17. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
18. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
19. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
Morin MJ
Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
[TBL] [Abstract][Full Text] [Related]
20. Novel inhibitors of the PI3K family.
Carnero A
Expert Opin Investig Drugs; 2009 Sep; 18(9):1265-77. PubMed ID: 19589091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
